Seroprevalence of Measles, Rubella, Tetanus, and Diphtheria Antibodies among Children in Haiti, 2017.
Child
Child, Preschool
Diphtheria
/ epidemiology
Female
Haiti
/ epidemiology
Humans
Male
Measles
/ epidemiology
Measles Vaccine
/ administration & dosage
Rubella
/ epidemiology
Rubella Vaccine
/ administration & dosage
Seroepidemiologic Studies
Tetanus
/ epidemiology
Vaccination
Vaccination Coverage
Journal
The American journal of tropical medicine and hygiene
ISSN: 1476-1645
Titre abrégé: Am J Trop Med Hyg
Pays: United States
ID NLM: 0370507
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
4
7
2020
medline:
24
11
2020
entrez:
4
7
2020
Statut:
ppublish
Résumé
In Haiti, measles, rubella, and maternal and neonatal tetanus have been eliminated, but a diphtheria outbreak is ongoing as of 2019. We conducted a nationally representative, household-based, two-stage cluster survey among children aged 5-7 years in 2017 to assess progress toward maintenance of control and elimination of selected vaccine-preventable diseases (VPDs). We stratified Haiti into West region (West department, including the capital city) and non-West region (all other departments). We obtained vaccination history and dried blood spots, and measured antibody concentrations to VPDs on a multiplex bead assay. Among 1,146 children, national seropositivity was 83% (95% CI: 80-86%) for tetanus, 83% (95% CI: 81-85%) for diphtheria, 87% (95% CI: 85-89%) for measles, and 84% (95% CI: 81-87%) for rubella. None of the children had long-term immunity to tetanus or diphtheria (IgG concentration ≥ 1 international unit/mL). Seropositivity in the West region was lower than that in the non-West region. Vaccination coverage was 68% (95% CI: 61-74%) for ≥ 3 doses of tetanus- and diphtheria-containing vaccine (DTP3), 84% (95% CI: 80-87%) for one dose of measles-rubella vaccine (MR1), and 20% (95% CI: 16-24%) for MR2. The seroprevalence of measles, rubella, and diphtheria antibodies is lower than population immunity levels needed to prevent disease transmission, particularly in the West region; reintroduction of these diseases could lead to an outbreak. To maintain VPD control and elimination, Haiti should achieve DTP3 and MR2 coverage ≥ 95%, and include tetanus and diphtheria booster doses in the routine immunization schedule.
Identifiants
pubmed: 32618256
doi: 10.4269/ajtmh.20-0112
pmc: PMC7543806
doi:
Substances chimiques
Measles Vaccine
0
Rubella Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1717-1725Références
Am J Trop Med Hyg. 2017 Feb 8;96(2):415-420
pubmed: 27920395
PLoS One. 2016 Feb 10;11(2):e0148605
pubmed: 26863307
Vaccine. 1992;10(13):928-35
pubmed: 1471414
Eur J Pediatr. 2006 Jan;165(1):14-8
pubmed: 16249929
Epidemiol Infect. 2000 Aug;125(1):113-25
pubmed: 11057967
Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S578-85
pubmed: 26553691
Front Immunol. 2018 Jun 18;9:1402
pubmed: 29967622
Wkly Epidemiol Rec. ;92(6):53-76
pubmed: 28185446
J Trop Pediatr. 2019 Apr 1;65(2):183-187
pubmed: 29688558
Vaccine. 2016 Nov 4;34(46):5495-5503
pubmed: 27692772
PLoS One. 2016 Mar 02;11(3):e0149970
pubmed: 26934372
J Infect Dis. 2018 Jul 2;218(3):355-364
pubmed: 29562334
Wkly Epidemiol Rec. ;92(17):205-27
pubmed: 28459148
Clin Vaccine Immunol. 2016 Jul 05;23(7):546-54
pubmed: 27053629
Pan Afr Med J. 2017 Jun 22;27(Suppl 3):24
pubmed: 29296159
Vaccine. 2012 Nov 19;30(49):7111-7
pubmed: 23022148
Am J Trop Med Hyg. 2017 Feb 8;96(2):312-318
pubmed: 27895279
Vaccine. 2012 Feb 21;30(9):1746-51
pubmed: 22227146
Clin Vaccine Immunol. 2011 Jul;18(7):1183-6
pubmed: 21613460
Trop Med Int Health. 2014 Sep;19(9):1105-15
pubmed: 25041586
MMWR Morb Mortal Wkly Rep. 2017 Oct 27;66(42):1148-1153
pubmed: 29073125
Am J Trop Med Hyg. 2019 Jul;101(1):214-219
pubmed: 31115298
Vaccine. 2014 Sep 3;32(39):4893-900
pubmed: 25045821
Trop Med Int Health. 2016 Sep;21(9):1086-98
pubmed: 27300255
Gates Open Res. 2019 Mar 21;3:923
pubmed: 32270134
Am J Trop Med Hyg. 2017 Oct;97(4_Suppl):28-36
pubmed: 29064356
Vaccine. 2011 Oct 26;29(46):8215-21
pubmed: 21893149